GDFT and Postoperative Cognitive Function in Geriatric Cancer Surgery
Intraoperative Goal-Directed Fluid Therapy and Postoperative Cognitive Outcomes in Geriatric Patients Undergoing Major Cancer Surgeries: A Comparative Study
1 other identifier
observational
180
1 country
1
Brief Summary
Postoperative cognitive decline remains a common and clinically significant complication among geriatric patients undergoing major abdominal cancer surgery. Age-related physiological vulnerability, impaired cerebral autoregulation, and perioperative hemodynamic instability contribute to the development of postoperative neurocognitive impairment. Goal-directed fluid therapy (GDFT), guided by dynamic hemodynamic parameters, has been proposed as an individualized approach to optimize tissue perfusion while avoiding both hypovolemia and fluid overload. Non-invasive monitoring technologies, such as pleth variability index (PVI) and perfusion index (PI), allow continuous assessment of fluid responsiveness without the risks associated with invasive monitoring, making them particularly suitable for elderly surgical populations. This prospective observational cohort study aims to evaluate the association between intraoperative PVI/PI-guided GDFT and postoperative cognitive outcomes in geriatric patients undergoing elective major abdominal cancer surgery. Patients are managed according to routine clinical practice, either with individualized GDFT or conventional fluid therapy, as determined by the attending anesthesiologist. The primary outcome is the change in cognitive function, assessed using Mini-Mental State Examination (MMSE) scores from baseline to postoperative day 1 and postoperative day 7. Longitudinal changes in cognitive function will be analyzed using adjusted statistical models to account for repeated measurements over time and potential confounding factors, including age, ASA physical status, duration of surgery, and intraoperative blood loss. Secondary outcomes include intraoperative fluid administration, hemodynamic parameters, estimated blood loss, and net fluid balance. The study is designed to provide clinically relevant evidence on whether individualized, non-invasive hemodynamic monitoring strategies are associated with improved perioperative physiological stability and early postoperative cognitive recovery in elderly surgical patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedFirst Submitted
Initial submission to the registry
February 23, 2026
CompletedFirst Posted
Study publicly available on registry
February 27, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
March 30, 2026
CompletedApril 30, 2026
April 1, 2026
1 year
February 23, 2026
April 26, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change in Postoperative Cognitive Function (MMSE Scores)
The primary outcome is the assessment of cognitive function using the Mini-Mental State Examination. The MMSE is a 30-point questionnaire used to measure cognitive impairment. Scores range from 0 to 30, where lower scores indicate greater cognitive impairment (e.g., \<24 is typically considered indicative of cognitive dysfunction). The study will compare the incidence of POCD between the GDFT group (monitored via Masimo Root PVI/PI) and the conventional fluid therapy group.
Preoperative (Baseline), Postoperative Day 1, and Postoperative Day 7.
Secondary Outcomes (6)
Total Intraoperative Fluid Volume
From induction of anesthesia to the end of surgery (assessed intraoperatively, up to approximately 4 hours)
Intraoperative Mean Arterial Pressure (MAP)
Baseline (pre-induction), intraoperative 1st hour, intraoperative 2nd hour
Intraoperative Heart Rate (HR)
Intraoperative period (baseline, 1st hour, 2nd hour)
Estimated Blood Loss
Intraoperative period
Net Fluid Balance
From induction of anesthesia to the end of surgery (calculated at the end of surgery, over an intraoperative period of up to approximately 4 hours).
- +1 more secondary outcomes
Study Arms (2)
GDFT Group (Masimo Root Guided)
Patients in this group will receive intraoperative GDFT. Hemodynamic monitoring will be performed using the Masimo Root device. Fluid administration (crystalloids and/or colloids) will be titrated based on real-time PVI and PI values to maintain optimal stroke volume and tissue perfusion. The goal is to achieve individualized hemodynamic stability throughout the major abdominal cancer surgery.
Conventional Group (Standard Care)
Patients in this group will receive conventional fluid therapy based on standard clinical guidelines. Fluid requirements will be calculated using the traditional "4:2:1" rule (physiological requirement + estimated blood loss + third-space fluid loss). Intraoperative fluid management will rely on routine monitoring (heart rate, mean arterial pressure, and urine output) without the use of advanced hemodynamic parameters like PVI or PI from the Masimo Root device
Interventions
Use of PVI and PI parameters to guide intraoperative fluid titration.
Eligibility Criteria
The study population consists of geriatric patients (aged 65 and older) scheduled for elective major abdominal cancer surgery at the University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. Participants will be selected from patients who meet the inclusion criteria and provide informed consent during their preoperative evaluation in the anesthesiology clinic
You may qualify if:
- Age ≥ 65 years (geriatric patients)
- Scheduled for elective major abdominal cancer surgery
- American Society of Anesthesiologists (ASA) Physical Status I-IV
- Eastern Cooperative Oncology Group (ECOG/WHO/Zubrod) performance status ≥ 2
- Ability to complete cognitive assessments
- Provision of written informed consent
You may not qualify if:
- Severe cardiac dysfunction (Cardiac Index ≤ 2.2 L/min/m²)
- History of neurological or psychiatric disorders (e.g., dementia, Alzheimer's disease)
- Use of medications that significantly affect cognitive function
- Severe hepatic or renal failure
- Prior chemotherapy or radiotherapy before surgery
- Intraoperative or perioperative blood transfusion
- Prolonged mechanical ventilation (inability to extubate immediately after surgery)
- Pre-existing cognitive impairment (baseline Mini-Mental State Examination \[MMSE\] score \< 24)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital Clinic of Anesthesiology and Rea
Ankara, Yenimahalle, 06200, Turkey (Türkiye)
Related Publications (3)
Wu B, Guo Y, Min S, Xiong Q, Zou L. Postoperative cognitive dysfunction in elderly patients with colorectal cancer: A randomized controlled study comparing goal-directed and conventional fluid therapy. Open Med (Wars). 2024 Mar 27;19(1):20240930. doi: 10.1515/med-2024-0930. eCollection 2024.
PMID: 38584828BACKGROUNDZhang N, Liang M, Zhang DD, Xiao YR, Li YZ, Gao YG, Cai HD, Lin XZ, Lin CZ, Zeng K, Wu XD. Effect of goal-directed fluid therapy on early cognitive function in elderly patients with spinal stenosis: A Case-Control Study. Int J Surg. 2018 Jun;54(Pt A):201-205. doi: 10.1016/j.ijsu.2018.04.007. Epub 2018 Apr 17.
PMID: 29678619BACKGROUNDZhang J, Qiao H, He Z, Wang Y, Che X, Liang W. Intraoperative fluid management in open gastrointestinal surgery: goal-directed versus restrictive. Clinics (Sao Paulo). 2012 Oct;67(10):1149-55. doi: 10.6061/clinics/2012(10)06.
PMID: 23070341BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
February 23, 2026
First Posted
February 27, 2026
Study Start
December 1, 2024
Primary Completion
December 1, 2025
Study Completion
March 30, 2026
Last Updated
April 30, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share
Individual participant data (IPD) will not be shared to ensure patient confidentiality and data privacy, as per the ethical committee approval and institutional policies. Only aggregated study results will be published.